Labcorp reported Q3 2025 revenue of $3.56 billion and net income of $261.1 million. Adjusted EPS grew to $4.18 and operating income improved significantly due to strong Diagnostics and Central Labs demand, innovation, and recent acquisitions.

Labcorp reported strong Q2 2025 results with higher revenue and net income, driven by strong demand, new oncology test launches, and expanded partnerships with hospitals. The company raised its full-year revenue, EPS, and free cash flow guidance.

Labcorp delivered solid first-quarter results with revenue growth and the successful launch of new diagnostic tests, despite a dynamic macroeconomic environment.

Labcorp announced its Q4 2024 and full year results, demonstrating strong performance. Q4 revenue reached $3.33 billion compared to $3.03 billion in the previous year. The company's diluted EPS for Q4 was $1.70, a significant increase from $(1.95) in the prior year. Adjusted EPS for Q4 was $3.45 compared to $3.30 last year. Free cash flow for Q4 was $665.1 million, up from $412.4 million year-over-year. For full year 2024, revenue was $13.01 billion versus $12.16 billion in 2023, diluted EPS was $8.84 versus $4.33, adjusted EPS was $14.57 versus $13.56, and free cash flow was $1.10 billion versus $748.7 million.

Labcorp announced its Q3 2024 results, showcasing strong performance in Diagnostics and Biopharma Laboratories. Revenue increased to $3.28 billion, and adjusted EPS reached $3.50. The company also updated its full-year guidance, reflecting confidence in continued growth.

Labcorp reported a strong second quarter in 2024, with revenue increasing by 6.2% to $3.22 billion and diluted EPS rising to $2.43. The company's performance was driven by organic growth in its base business and contributions from acquisitions. Labcorp has updated its full-year guidance to reflect this strong performance and the acquisition of Invitae.

Labcorp announced its first quarter 2024 results, with revenue increasing by 4.6% to $3.18 billion. Diluted EPS grew to $2.69, and adjusted EPS reached $3.68. The company updated its full-year guidance, raising the midpoint and narrowing the range of adjusted EPS to $14.45 to $15.35, while free cash flow is expected to remain between $1.00 billion and $1.15 billion.

Labcorp's Q4 2023 saw a revenue increase of 3.5% to $3.03 billion, driven by organic growth and acquisitions. However, the company reported a net loss of $(166.8) million, or $(1.95) per share, compared to a net income of $37.1 million, or $0.42 per share in Q4 2022. Adjusted EPS was $3.30, up from $3.05 in the prior year. The results were impacted by impairment charges and a decrease in COVID-19 testing revenue.

Labcorp announced strong third quarter results, with revenue increasing by 6.6% to $3.06 billion, driven by 14.0% growth in the Base Business. Diluted EPS was reported at $2.11, and adjusted EPS reached $3.38. The company updated its full-year guidance, projecting adjusted EPS of $13.25 to $13.75 and free cash flow of $0.85 billion to $0.95 billion.

Labcorp announced strong Q2 2023 results with revenue increasing by 4% to $3.0 billion, driven by a 13% growth in the Base Business. Diluted EPS was $1.74, and adjusted EPS was $3.42. The company completed the spin-off of Fortrea and announced a $1.0 billion accelerated share repurchase program.

Labcorp's first quarter results showed a decrease in revenue and earnings compared to the previous year, primarily due to a decline in COVID-19 testing. However, the company's base business experienced growth, and it is progressing with the spin-off of its Clinical Development business. The company updated its full-year guidance for adjusted EPS and free cash flow.

Labcorp's Q4 2022 results showed a revenue of $3.7 billion, a decrease from $4.1 billion in the previous year, with diluted EPS at $0.86 compared to $5.75. The company experienced a decrease in COVID-19 testing revenue but saw growth in its base business. They also provided full-year 2023 guidance, including adjusted EPS of $16.00 to $18.00 and free cash flow of $1.0 billion to $1.2 billion.

Labcorp reported a decrease in revenue for Q3 2022, with $3.61 billion compared to $4.06 billion in Q3 2021. Diluted EPS decreased to $3.90 from $6.05, and adjusted EPS decreased to $4.68 from $6.82. The company is progressing with the spin-off of its Clinical Development business and has completed transactions to establish a long-term relationship with Ascension.

Labcorp reported a decrease in revenue to $3.7 billion, a diluted EPS of $3.87, and an adjusted EPS of $4.96. The company announced plans to spin-off its Clinical Development business to enhance growth and focus. Despite revenue decline due to reduced COVID-19 testing, the base business showed growth, and the company launched several innovative diagnostics.

Labcorp's Q1 2022 revenue reached $3.9 billion, a decrease from $4.2 billion year-over-year. Diluted EPS was $5.23, and adjusted EPS was $6.11. The company initiated a quarterly dividend and updated its full-year guidance, with adjusted EPS expected to be $18.25 to $21.00 and free cash flow projected at $1.7 billion to $1.9 billion.

Labcorp's Q4 2021 revenue was $4.06 billion, a decrease of 9.7% compared to Q4 2020. Diluted EPS was $5.75, down from $9.54 in the same period last year. The company's base business grew by 5.0%, offsetting a decline in COVID-19 testing revenue. Labcorp provided 2022 guidance, including adjusted EPS of $17.25 to $21.25 and free cash flow of $1.7 billion to $1.9 billion.

Labcorp reported a revenue increase of 4.3% to $4.06 billion compared to Q3 2020. Diluted EPS decreased to $6.05 from $7.17 in the same period last year, while adjusted EPS was $6.82 compared to $8.41 in Q3 2020. The company raised its full-year guidance for revenue, adjusted EPS, and free cash flow.

Labcorp announced strong second-quarter results, with revenue increasing by 38.7% to $3.84 billion and diluted EPS rising to $4.76. The company raised its full-year guidance, reflecting its improved outlook.

Labcorp announced strong Q1 2021 results with revenue increasing by 47.4% to $4.16 billion and adjusted EPS rising to $8.79. The company raised its full-year guidance, reflecting improved recovery in the base businesses and sustained COVID-19 testing contributions.

Labcorp announced strong Q4 2020 results with a 52% increase in revenue to $4.5 billion and a significant rise in diluted EPS to $9.54, driven by COVID-19 testing and improvements in the base business. The company also provided full year 2021 guidance, expecting adjusted EPS between $19.00 and $23.00 and free cash flow between $1.7 billion and $1.9 billion.

LabCorp announced strong Q3 2020 results, with revenue increasing by 33.0% to $3.9 billion and diluted EPS rising to $7.17. The company's performance was driven by COVID-19 testing and improvements in its base business, leading to increased operating income and free cash flow. LabCorp also decided to return all money received from the CARES Act Provider Relief Funds due to its improved financial outlook.

LabCorp announced its Q2 2020 results, with revenue of $2.77 billion, a decrease of 3.9% compared to Q2 2019. Diluted EPS increased by 22.8% to $2.37, while adjusted EPS decreased by 12.3% to $2.57. The company processed over 8.5 million molecular COVID-19 tests and increased testing capacity.

LabCorp announced its Q1 2020 results with a revenue of $2.82 billion, a 1% increase compared to last year. Diluted EPS was ($3.27), including goodwill and other asset impairments. Adjusted EPS was $2.37, negatively impacted by COVID-19. Free cash flow was $97 million, up 36% year-over-year. The company withdrew its 2020 guidance due to the unpredictability of the COVID-19 pandemic.

LabCorp reported a 6% increase in revenue for Q4 2019, reaching $3.0 billion. Diluted EPS increased to $2.32, and adjusted EPS rose by 13% to $2.86. Free cash flow also increased by 21% to $442 million.